Hilary A. Blacklock
Middlemore, AUK, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Variation in immunoglobulin use and impact on survival in myeloma.
Journal: EJHaem
Published: May 03, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
Journal: British journal of haematology
Published: March 29, 2024
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Journal: British journal of haematology
Published: March 31, 2022
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 20, 2021
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Journal: European journal of haematology
Published: May 04, 2021
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Journal: Bone marrow transplantation
Published: October 21, 2020
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 19, 2020
Coronavirus (COVID-19), Coagulation, and Exercise: Interactions That May Influence Health Outcomes.
Journal: Seminars in thrombosis and hemostasis
Published: September 04, 2020
The critical role of histology in distinguishing sarcoidosis from common variable immunodeficiency disorder (CVID) in a patient with hypogammaglobulinemia.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: June 26, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Haematology
Published: February 22, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 28, 2019
Distinctive features of polycythaemia vera in New Zealand Polynesians.
Journal: The New Zealand medical journal
Published: September 21, 2018
Last Updated: 09/26/2026